ReviewExpert review of vaccines2016
Leishmania vaccine development: exploiting the host-vector-parasite interface.
Review in Expert review of vaccines, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Interventions for American cutaneous and mucocutaneous leishmaniasis.The Cochrane database of systematic reviews · 2020Pooled it
- Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Trial
- Acquired tick resistance inInfection and immunity · 2025Article
- Research progress toward arthropod salivary protein vaccine development for vector-borne infectious diseases.PLoS neglected tropical diseases · 2024Review
- Tick saliva and its role in pathogen transmission.Wiener klinische Wochenschrift · 2023Article
- Review
- Healed Lesions of Human Cutaneous Leishmaniasis Caused ByFrontiers in cellular and infection microbiology · 2022Article
- Overcoming roadblocks in the development of vaccines for leishmaniasis.Expert review of vaccines · 2021Review
- Vector saliva controlled inflammatory response of the host may represent the Achilles heel during pathogen transmission.The journal of venomous animals and toxins including tropical diseases · 2021Article
- Evaluation of immune response toParasitology · 2020Article
- Vaccinating against mosquitoes: anticipating the unexpected.Lancet (London, England) · 2020Article
- Article
- Immune Profile of the Nasal Mucosa in Patients with Cutaneous Leishmaniasis.Infection and immunity · 2020Article
- A new multi-epitope peptide vaccine induces immune responses and protection against Leishmania infantum in BALB/c mice.Medical microbiology and immunology · 2020Article
- Lactococcus lactis expressing sand fly PpSP15 salivary protein confers long-term protection against Leishmania major in BALB/c mice.PLoS neglected tropical diseases · 2020Article
- Functional and structural similarities of D7 proteins in the independently-evolved salivary secretions of sand flies and mosquitoes.Scientific reports · 2019Article
- Time to Micromanage the Pathogen-Host-Vector Interface: Considerations for Vaccine Development.Vaccines · 2019Review
- The PAGODAS protocol: pediatric assessment group of dengue and Aedes saliva protocol to investigate vector-borne determinants of Aedes-transmitted arboviral infections in Cambodia.Parasites & vectors · 2018Article
- Mosquito Saliva: The Hope for a Universal Arbovirus Vaccine?The Journal of infectious diseases · 2018Review
- Human Interleukin-32γ Plays a Protective Role in an Experimental Model of Visceral Leishmaniasis in Mice.Infection and immunity · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
Visceral leishmaniasis (VL) is a disease transmitted by phlebotomine sand flies, fatal if untreated, and with no available human vaccine. In rodents, cellular immunity to Leishmania parasite proteins as well as salivary proteins of the sand fly is associated with protection, making them worthy targets for further exploration as vaccines. This review discusses the notion that a combination vaccine including Leishmania and vector salivary antigens may improve vaccine efficacy by targeting the parasite at its most vulnerable stage just after transmission. Furthermore, we put forward the notion that better modeling of natural transmission is needed to test efficacy of vaccines. For example, the fact that individuals living in endemic areas are exposed to sand fly bites and will mount an immune response to salivary proteins should be considered in pre-clinical and clinical evaluation of leishmaniasis vaccines. Nevertheless, despite remaining obstacles there is good reason to be optimistic that safe and effective vaccines against leishmaniasis can be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.